NVS 241220 125.00P (NVS241220P125000) Stock Options, News & Quotes

US OptionsDetailed Quotes

NVS241220P125000

Watchlist

10.80
0.000.00%

15min DelayClose Dec 10 15:59 ET

0.00High0.00Low

Intraday

5D
Daily

News

Monte Rosa Closes Global License Agreement With Novartis
MT Newswires07:45 ET
Barclays Sticks to Its Sell Rating for Novartis AG (NOVN)
TipRanks01:25 ET · Ratings
Raymond James, Cantor Bullish on UniQure Following FDA Update
Seeking Alpha13:11 ET
Novartis Says Longer-Term Data Highlight Kisqali's Efficacy as Early Breast Cancer Treatment
MT NewswiresDec 10 10:54 ET
Deutsche Bank Sticks to Their Hold Rating for Novartis AG (NOVN)
TipRanksDec 10 06:27 ET · Ratings
Novartis Announces Positive Results From Late-Stage Study on Fabhalta
Zacks Dec 9 12:30 ET

Comments

Asherboy88

2 minutes ago

$Novartis AG (NVS.US)$ what is happening ?? keeps going down

Movers and Shakers

Nov 21 07:11

Columns Today's Pre-Market Movers and Top Ratings | MSTR, NVDA, SNOW, PANW and More

Morning Movers
Gapping up
$Deere (DE.US)$ 's stock rose by 1.6% following their announcement of fourth-quarter earnings that surpassed analyst forecasts, despite substantial market hurdles.
Cryptocurrency-related stocks experienced a widespread surge. $MicroStrategy (MSTR.US)$ saw a significant increase, jumping over 13%, while $MARA Holdings (MARA.US)$ climbed more than 11%.
$Snowflake (SNOW.US)$ 's shares surged 23.3% as ...

Bitcoin breaks the $100,000 mark: How high could it go from here?

10xStockPicks

Nov 15 08:23

ESPR Will Propel Higher, Events This Weekend & Analyst Event Next Week, Stock Price

This $2 Stock Remains Deeply Undervalued, Profitable in 2025, Offers 10x Upside within 20 Months
Hugely Undervalued $2 Biotech With 21% Held Short $16 Price Target, Takeover Candidate, Soon Profitable. Fund that owns $Viking Therapeutics (VKTX.US)$ since 2022 below $10 a share is also investing in ESPR and expects the company will be a block buster.
This unique biotech $Esperion Therapeutics (ESPR.US)$ Esper...

+18

thz stock ful of sht

Nov 15 01:20

DOWN

$Eli Lilly and Co (LLY.US)$ $Novo-Nordisk A/S (NVO.US)$ $Johnson & Johnson (JNJ.US)$ $AbbVie (ABBV.US)$ $Merck & Co (MRK.US)$ $ROCHE HOLDING AG (RHHBY.US)$ $Novartis AG (NVS.US)$ $AstraZeneca (AZN.US)$ $Amgen (AMGN.US)$ $Pfizer (PFE.US)$

10xStockPicks

Nov 8 08:28

This $2 Stock Remains Deeply Undervalued, Profitable in 2025, Offers 10x Upside within 20 Months

Hugely Undervalued $2 Biotech With 21% Held Short $16 Price Target, Takeover Candidate, Soon Profitable. Fund that owns $Viking Therapeutics (VKTX.US)$ since 2022 below $10 a share is also investing in ESPR and expects the company will be a block buster.
This unique biotech $Esperion Therapeutics (ESPR.US)$ Esperion has the only FDA approved statin alternative drugs NEXLIZET & NEXLETOL for Primary...

+18